Evidence map›Paper›PMID 38041509›Full record

ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Engineering Versatile Nanomedicines for Ultrasonic Tumor Immunotherapy.

Jing Liang, Xiaohui Qiao, Luping Qiu, Huning Xu, Huijing Xiang, Hong Ding, Yu Chen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jing LiangDepartment of Ultrasound, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Xiaohui QiaoDepartment of Ultrasound, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Luping QiuDepartment of Ultrasound, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Huning XuDepartment of Ultrasound, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Huijing XiangMaterdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 2000444, China.
Hong DingDepartment of Ultrasound, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Yu ChenMaterdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 2000444, China.ORCID 0000-0002-8206-3325

Funding

Basic Research Program of Shanghai Municipal Government 21JC1406002Key Science and Technology Research and Development Projects of Jiangxi Province 20223BBH80014National Natural Science Foundation of China 3217139National Natural Science Foundation of China 82272017National Science Fund for Excellent Young Scholars T2322018Shanghai Rising-Star Program 22QA1403600Shanghai Science and Technology Program 21010500100Shanghai Science and Technology Program 22140901700Shanghai Science and Technology Program 22142202200Shanghai Science and Technology Program 22DZ2204700Shanghai Shuguang Program 21SG39
6 · The paper itself

Abstract

Due to the specific advantages of ultrasound (US) in therapeutic disease treatments, the unique therapeutic US technology has emerged. In addition to featuring a low-invasive targeted cancer-cell killing effect, the therapeutic US technology has been demonstrated to modulate the tumor immune landscape, amplify the therapeutic effect of other antitumor therapies, and induce immunosensitization of tumors to immunotherapy, shedding new light on the cancer treatment. Tremendous advances in nanotechnology are also expected to bring unprecedented benefits to enhancing the antitumor efficiency and immunological effects of therapeutic US, as well as therapeutic US-derived bimodal and multimodal synergistic therapies. This comprehensive review summarizes the immunological effects induced by different therapeutic US technologies, including ultrasound-mediated micro-/nanobubble destruction (UTMD/UTND), sonodynamic therapy (SDT), and focused ultrasound (FUS), as well as the main underlying mechanisms involved. It is also discussed that the recent research progress of engineering intelligent nanoplatform in improving the antitumor efficiency of therapeutic US technologies. Finally, focusing on clinical translation, the key issues and challenges currently faced are summarized, and the prospects for promoting the clinical translation of these emerging nanomaterials and ultrasonic immunotherapy in the future are proposed.

Indexed as

NeoplasmsUltrasonic TherapyHumansImmunotherapyNanomedicineUltrasonicsimmunotherapynanomedicinesonodynamic therapytumor therapyultrasound technologies

Identifiers

PMID38041509
PMCPMC10797440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.